// App-Quantinova.ai

CT532 : Phase 1/2 results of ceralasertib (Cerala as monotherapy or in combination with acalabrutinib (Acala in high-risk relapsed/refractory (R/R chronic lymphocytic leukemia (CLL

Researchers

Presenter

  • Wojciech Jurczak

Principal Investigators

  • Nagah Elmusharaf

  • Christopher P. Fox

  • William Townsend

  • Amanda G. Paulovich

  • Shringi Sharma

  • Graeme Parr

  • Veerendra Munugalavadla

  • Fanny Krantz

  • Helen Yang

  • Emma Dean

  • Richa Manwani

  • Peter Hillmen

Medical Centers

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • University Hospital of Wales, Cardiff, United Kingdom

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • University College London Hospitals NHS Trust, NIHR BRC Clinical Research Facility, London, United Kingdom

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • AstraZeneca, South San Francisco, CA

  • Astra Zeneca, Cambridge, United Kingdom

  • St. James's University Hospital, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • Tumor protein p53

Drug/Treatment

  • ACP-196

  • TP53

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • I/II

Study Id's

  • NCT03328273

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved